Akebia Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AX9.F | 42C.SI | BCRX | GUD.TO | B6E.F | 002038.SZ | |
|---|---|---|---|---|---|---|
| Market cap | 165.49M | 515.12M | 2.11B | 1.11B | 15.44B | 5.37B |
| P/E (TTM) | — | — | — | 75.3 | 25.6 | — |
| Forward P/E | -0.8 | 247.4 | 10.0 | 43.5 | — | — |
| Price/book | 7.3 | 33.6 | -14.7 | 1.4 | 0.4 | 1.1 |
| Dividend yield | — | — | — | — | — | 0.19% |
| 1-year change | −65.57% | +259.26% | +17.21% | +92.81% | +43.32% | −31.88% |
| Today | −5.12% | −3.09% | −3.85% | +0.36% | +1.98% | +1.55% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All AX9.F news ›Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Has Average Price Target of $3.90
Get Our Latest Research Report on AKBA Akebia Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease and related conditions. The company's primary areas of…
Akebia Therapeutics and U.S. Renal Care Present Positive VOICE Trial Data for Vafseo at ASN Kidney Week 2026
Akebia Therapeutics announces VOICE trial data showing vadadustat improves safety outcomes for anemia in dialysis patients versus ESA. The VOICE trial examined the safety and efficacy of vadadustat for treating anemia in dialysis patients…
Akebia Therapeutics (NASDAQ:AKBA) Upgraded to Hold at Wall Street Zen
Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Sunday, Wall Street Zen reports. Get Our Latest Stock Analysis…
Akebia Therapeutics Receives Nasdaq Notice for Minimum Bid Price Non-Compliance
Nasdaq's Listing Qualifications Department notified Akebia on October 21, 2026, that it failed to meet the minimum $1.00 bid price requir ... On October 23, 2026, Akebia Therapeutics, Inc. announced via a Form 8-K that it received a…
Comparing Keros Therapeutics (NASDAQ:KROS) and Akebia Therapeutics (NASDAQ:AKBA)
Posted by Danessa Lincoln on Oct 24th, 2026 Keros Therapeutics (NASDAQ:KROS – Get Free Report) and Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will…
More from 1 other outlet
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
Yiren Digital Provides Further Update on Operations Akebia Therapeutics (AKBA) will hold investor meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026. CEO John P. Butler, Chief R&D and Medical Officer Dr.…
Akebia Therapeutics: Nicholas Grund to resign Nov. 6
The commercial chief at Akebia Therapeutics (AKBA) plans to resign for personal reasons. Stock Titan Akebia Therapeutics: Nicholas Grund to resign Nov. 6 Nicholas Grund's consulting engagement is scheduled to continue through April 30,…
Transcript : Akebia Therapeutics, Inc., Q2 2026 Earnings Call, Aug 05, 2026
Presentation Operator MessageOperator Ladies and gentlemen, thank you for standing by. This is Roy, and I will be your conference operator today. At this time, I would like to welcome everyone to Transcript : Akebia Therapeutics, Inc., Q2…
Akebia Therapeutics, Inc. : Insider Transactions
Follow insider transactions on Akebia Therapeutics, Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Akebia Therapeutics, Inc. Latest insider transactions for…
Akebia Therapeutics, Inc.: News in other languages | AKBA | US00972D1054
Akebia Therapeutics, Inc.: News, information and stories for Akebia Therapeutics, Inc. | Nasdaq: AKBA | Nasdaq Other languages Akebia Therapeutics, Inc. All financial news and data tailored to specific country editions
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com9
- stocktitan.net2
- themarketsdaily.com2
- defenseworld.net1
- kalkinemedia.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.